Clinical analysis of hemorrhagic cystitis in children and adolescents with hematological diseases post haplo-hematopoietic stem cell transplantation
10.3760/cma.j.issn.0253-2727.2018.10.009
- VernacularTitle: 儿童及青少年血液病患者单倍型造血干细胞移植后合并出血性膀胱炎临床分析
- Author:
Yunxia XIE
1
;
Yu WANG
;
Xiaojun HUANG
;
Lanping XU
;
Xiaohui ZHANG
;
Kaiyan LIU
;
Cenhua YAN
;
Fengrong WANG
;
Yuqian SUN
;
Jun KONG
;
Yanqun GAO
;
Hongyu SHI
;
Duoping LIU
;
Yifei CHENG
Author Information
1. Institute of Hematology, People’s Hospital, Peking University, Beijing 100044, China
- Publication Type:Journal Article
- Keywords:
Haplo-hematopoietic stem cell transplantation;
Hemorrhagic cystitis;
Risk factors
- From:
Chinese Journal of Hematology
2018;39(10):833-838
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the incidence and clinical features to probe the risk factors of hemorrhagic cystitis (HC) in children and adolescents with hematological diseases post haplo-hematopoietic stem cell transplantation (haplo-HSCT) .
Methods:Medical records of 62 children and 27 adolescents with hematological diseases treated with haplo-HSCT between 2015 and 2016 were analyzed.
Results:Of 89 cases (56 boys and 33 girls) , 44 patients were diagnosed with ALL, 33 AML, 3 AHL and 9 MDS. HC occurred in 32 of the 89 patients with an incidence of 36%, including 6 with grade Ⅰ, 16 with grade Ⅱ, 8 with grade Ⅲ, 2 with grade Ⅳ HC, respectively. The median time of HC onset was 25 days (range 2-55 days) after haplo-HSCT with the median duration as 19 days (range 3-95 days) , all of them were cured. The incidence of HC was lower in the group of children than that in the group of adolescents (27.4% vs 55.6%, χ2=6.466, P<0.05) , and the incidence of HC was higher in the group of patients who were ≥5 years old than that in the group of patients who were <5 years old (0 vs 34%, χ2=4.043, P<0.05) .
Conclusion:HC is one of common complications in children and adolescents with hematological diseases post haplo-HSCT, older age was associated with increased mortality.